Consensus on the safety management of anti-angiogenic tyrosine kinase inhibitors in bone and soft tissue sarcoma treatment
10.3969/j.issn.1000-8179.2020.04.342
- VernacularTitle: 抗血管生成酪氨酸激酶抑制剂治疗骨与软组织肉瘤的药物安全管理共识
- Author:
Wei GUO
1
Author Information
1. Musculoskeletal Tumor Society, Chinese Medical Doctor Association, Chinese Sarcoma Study Group CSSG
- Publication Type:Journal Article
- Keywords:
Aa-TKIs;
Anti-angiogenesis;
Drug safety;
Osteosarcoma;
Sarcoma
- From:
Chinese Journal of Clinical Oncology
2020;47(4):163-171
- CountryChina
- Language:Chinese
-
Abstract:
Anti-angiogenesis-targeted drugs, especially anti-angiogenic tyrosine kinase inhibitors (aa-TKIs), are broadly used in the treatment of advanced bone and soft tissue sarcoma. The antitumor effects of Chinese domestically developed aa-TKIs, such as apatinib and anlotinib, were also demonstrated in several single-center or multi-center clinical studies. However, treatment-related adverse events (AEs) have limited the use of aa-TKIs. On Aug 30, 2019, the members of the Chinese Sarcoma Study Group conducted a thorough discussion on this issue and reached a consensus, focusing on the classification and treatment of common AEs that may occur during the use of aa-TKIs. The aim of this article is to improve our understanding and provide AE management guidance for clinicians as well as benefit patients using aa-TKIs.
